MedWatch

Fujifilm doubles bottom line in annual report

Despite a 12.5% cost increase compared to the preceding year, Fujifilm Diosynth Biotechnologies managed to increase its profit twofold in 2021/2022.

Fujifilm Diosynth Biotechnologies ligger i Hillerød nord for København. | Photo: Liselotte Plenov / Fotorummet / PR

With a profit of DKK 213m (USD 28.3m) in financial 2021/2022, Fujifilm Diosynth Biotechnologies has managed to more than double its bottom line compared to DKK 103.5m (USD 13.7m) the year before, according to the company’s recently released annual report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs